Subcutaneous · GLP-1 agonist
Dulaglutide
140 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
140
Ongoing
29
Recruiting
9
Completed
95
Sites
2,415
Countries
52
Endpoints
2,251
Composite endpoints
182
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
22
Phase 1/2
2
Phase 2
24
Phase 2/3
2
Phase 3
32
Phase 4
25
Not applicable
33
Trials by status
Not yet recruiting
7
By invitation
3
Recruiting
9
Active, not recruiting
10
Completed
95
Terminated
3
Suspended
1
Unknown
12
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
671
Safety / tolerability / PK
605
Cardiometabolic biomarkers
231
Weight & body composition
224
Cardiovascular outcomes
138
Other (unclassified)
104
Patient-reported / QoL
95
Other clinical outcomes
81
Renal / kidney
51
MASH / liver
34
Heart failure
17
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
154
Documented hypoglycemiaSafety/PK
104
Body weight, absolute change (kg)Weight
102
Fasting glucose, changeGlycemic
94
HbA1c <7.0% achievementGlycemic
87
AUC₀-∞Safety/PK
74
Heart rate, changeBiomarker
56
Postprandial glucoseGlycemic
55
CmaxSafety/PK
53
Treatment-emergent AEs (any)Safety/PK
49
Expanded / custom MACE compositeCV
44
Immunogenicity (ADA)Safety/PK
38
BMI, changeWeight
33
PancreatitisSafety/PK
31
Thyroid eventSafety/PK
30
HbA1c <6.5% achievementGlycemic
30
HOMA-IR (insulin sensitivity)Glycemic
29
TmaxSafety/PK
23
Total cholesterol, changeBiomarker
16
Triglycerides, changeBiomarker
15
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
140 of 140
Showing 1-25 of 140 trials